Skip to main navigation Immunocore Open menu News Releases Breadcrumb Home / Investor Relations / News & Events / News Releases Year None 11 November 2021 Immunocore to present at the Jefferies London Healthcare Conference 10 November 2021 Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update 9 November 2021 Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting 18 October 2021 Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel 22 September 2021 Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine 20 September 2021 Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial 13 September 2021 Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 10 September 2021 Immunocore to present at upcoming investor conferences 8 September 2021 Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma 24 August 2021 Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 126 Site - Shareholder Tools Print Page Email Alerts RSS Feeds Email Page Immunocore Site - Footer Social About us Our science Our therapy areas For patients News Careers Contact us Privacy and Social Media Guidelines Cookies Payments and Disclosures Clinical trials ©2021 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd To offer you a better experience, this site uses cookies, including those of third parties. To find out more and manage your preferences, consult the Cookie notice I Accept